Table 3.
Leukapheresis Products.
| Characteristic | G-CSF | PEG-G-CSF | P |
|---|---|---|---|
| 1st leukapheresis, median(range) | |||
| Total nucleated cells, 109/L | 287.0(130.0,500.6) | 343.6(179.9,476.8) | <.001 |
| CD34+ cells, 108/L | 8.3(2.1,26.6) | 9.6(2.2,31.3) | .166 |
| T+B+NK cells, 109/L | 62.7(5.0,129.9) | 70.1(3.5,127.0) | .244 |
| CD3+CD19- T cells, 109/L | 40.8(3.3,90.0) | 46.2(2.4,95.9) | .611 |
| CD3+CD4+ Th cells, 109/L | 23.3(1.6,49.3) | 24.6 (1.1,53.9) | .627 |
| CD3+CD8+ Ts cells, 109/L | 16.4 (1.6,44.0) | 16.7(1.2,49.4) | .907 |
| CD3-CD19+ B cells, 109/L | 11. 3 (0.4,25.9) | 15.1 (0.5,40.9) | .019 |
| CD3-CD16+CD56+ NK cells, 109/L | 6. 3(1.3,15.8) | 5.8 (1.4,15.7) | .534 |
| CD4+CD25+CD127dim/- Tregs, 108/L | 7.1(3.1,22.4) | 10.6(4.1,18.7) | .264 |
| Th/Ts | 1.35(0.63,3.42) | 1.40(0.56,4.05) | .591 |
| M-MDSC, 109/L | 3.5 (0.3,23.1) | 11.9(3.3,35.6) | <.001 |
| G-MDSC, 109/L | 29.0 (0.3,221.7) | 55.6(7.4,252.3) | .004 |
| 2nd leukapheresis, median(range) | |||
| Total nucleated cells, 109/L | 272.2(186.5,480.7) | 314.7(182.8,478.1) | .203 |
| CD34+ cells, 108/L | 3.7(1.4,13.0) | 4.3(1.4,11.6) | .476 |
| T+B+NK cells, 109/L | 52.4(30.4,99.9) | 51.4(9.1,72.8) | .375 |
| CD3+CD19- T cells, 109/L | 37.8(19.9,74.4) | 34.8(4.5,46.7) | .339 |
| CD3+CD4+ Th cells, 109/L | 19.1(12.4,41.2) | 18.4(2.2,34.6) | .708 |
| CD3+CD8+ Ts cells, 109/L | 15.4(6.0,26.8) | 12.7(2.0,17.5) | .073 |
| CD3-CD19+ B cells, 109/L | 8.6(4.2,28.7) | 8.7(1.6,19.8) | .586 |
| CD3-CD16+CD56+ NK cells, 109/L | 5.1(2.0,12.3) | 4.9(1.1,18.4) | .322 |
| Th/Ts | 1.46(0.81,3.57) | 1.53(0.88,4.39) | .286 |
| M-MDSC, 109/L | 7.6(0.3,16.7) | 8.9(4.4,35.6) | .743 |
| G-MDSC, 109/L | 59.3(0.3,180.9) | 126.1(35.9,252.3) | .094 |